Analysts expect Roivant Sciences Ltd (NASDAQ:ROIV) to announce sales of $10.13 million for the current quarter, according to Zacks. Two analysts have provided estimates for Roivant Sciences’ earnings, with estimates ranging from $6.00 million to $14.27 million. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Roivant Sciences will report full-year sales of $36.99 million for the current fiscal year, with estimates ranging from $31.70 million to $50.54 million. For the next financial year, analysts anticipate that the company will report sales of $44.88 million, with estimates ranging from $8.40 million to $92.11 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Roivant Sciences.
Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Monday, November 15th. The company reported ($0.87) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.06) by $0.19. The company had revenue of $13.99 million for the quarter, compared to the consensus estimate of $5.30 million.
Shares of ROIV opened at $7.95 on Friday. The company has a fifty day simple moving average of $9.93. Roivant Sciences has a 52-week low of $5.80 and a 52-week high of $16.76.
Roivant Sciences Company Profile
Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.
Featured Article: Why investors pay attention to retained earnings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.